Literature DB >> 1763144

A magnetic resonance imaging study of putamen nuclei in major depression.

M M Husain1, W M McDonald, P M Doraiswamy, G S Figiel, C Na, P R Escalona, O B Boyko, C B Nemeroff, K R Krishnan.   

Abstract

The basal ganglia are recognized as putative mediators of certain cognitive and behavioral symptoms of major depression. Moreover, patients with basal ganglia lesions have repeatedly exhibited significant affective symptomatology, including apathy, depressive mood, and psychosis. Using high resolution, axial T2 intermediate magnetic resonance images, and a systematic sampling stereologic method, we assessed putamen nuclei volumes in 41 patients with major depression (DSM-III) and 44 healthy volunteer controls of similar age. Depressed patients had significantly smaller putamen nuclei compared with controls. Age was negatively correlated with putamen size in both groups. These results are the first demonstration of diminished putamen volumes in depression and further support a role for basal ganglia structures in the etiopathogenesis of depression.

Entities:  

Mesh:

Year:  1991        PMID: 1763144     DOI: 10.1016/0925-4927(91)90001-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  54 in total

1.  Choice of cross size in stereology--a cautionary note.

Authors:  J M Dickson; H M Weavers; N Mitchell; E M Winter; I D Wilkinson; E J R VanBeek; P D Griffiths
Journal:  Neuroradiology       Date:  2003-09-13       Impact factor: 2.804

Review 2.  Magnetic resonance in patients with affective illness.

Authors:  W M McDonald; K R Krishnan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

Review 3.  Volumetric brain imaging studies in the elderly with mood disorders.

Authors:  John L Beyer
Journal:  Curr Psychiatry Rep       Date:  2006-02       Impact factor: 5.285

4.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

5.  Basal Ganglia Volumes: MR-Derived Reference Ranges and Lateralization Indices for Children and Young Adults.

Authors:  Aleksandra Wyciszkiewicz; Mikolaj A Pawlak
Journal:  Neuroradiol J       Date:  2014-09-25

6.  Volume deficits of subcortical nuclei in mood disorders A postmortem study.

Authors:  Hendrik Bielau; Kurt Trübner; Dieter Krell; Marcus W Agelink; Hans-Gert Bernstein; Renate Stauch; Christian Mawrin; Peter Danos; Lieselotte Gerhard; Bernhard Bogerts; Bruno Baumann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-17       Impact factor: 5.270

7.  Subcortical and medial temporal MR-detectable metabolite abnormalities in unipolar major depression.

Authors:  Gabriele Ende; Traute Demirakca; Sigrid Walter; Tim Wokrina; Alexander Sartorius; Dirk Wildgruber; Fritz A Henn
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-02       Impact factor: 5.270

8.  Depression in Parkinson's disease. Diffusion tensor imaging study.

Authors:  Hideaki Matsui; Kazuto Nishinaka; Masaya Oda; Hidekazu Niikawa; Kenichi Komatsu; Tamotsu Kubori; Fukashi Udaka
Journal:  J Neurol       Date:  2006-08-20       Impact factor: 4.849

9.  Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies.

Authors:  P Cédric M P Koolschijn; Neeltje E M van Haren; Gerty J L M Lensvelt-Mulders; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

10.  Bipolar I disorder and major depressive disorder show similar brain activation during depression.

Authors:  Michael A Cerullo; James C Eliassen; Christopher T Smith; David E Fleck; Erik B Nelson; Jeffrey R Strawn; Martine Lamy; Melissa P DelBello; Caleb M Adler; Stephen M Strakowski
Journal:  Bipolar Disord       Date:  2014-07-03       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.